Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Individuals with difficult vein access or bleeding disorders may also be at higher risk for complications, such as bruising or infection at the injection site
Cagrilintide mimics amylin, a hormone coreleased with insulin that promotes satiety and helps limit meal size
Active Ingredient : Semaglutide, a GLP-1 receptor agonist Mechanism of Action : According to FDA prescribing information, semaglutide works by: Increasing glucose-dependent insulin secretion Decreasing glucagon secretion Slowing gastric emptying Acting on centers in the brain that regulate appetite Clinical Trial Evidence - STEP Program : According to published data from the STEP 1 trial (New England Journal of Medicine, 2021): Study Design : 68-week randomized, double-blind, placebo-controlled trial 1,961 adults without diabetes Inclusion: BMI 30 or 27 with weight-related conditions Intervention: Once-weekly subcutaneous semaglutide 2.4 mg Lifestyle: 500-calorie deficit diet plus 150 minutes/week physical activity Primary Results : Semaglutide group: Average 14.9% body weight loss (approximately 33 lbs for 220 lb individual) Placebo group: Average 2.4% body weight loss (approximately 5 lbs for 220 lb individual) Difference: 12.4 percentage points (p 3 pounds/week associated with higher risk
MinJSJoSJLeeSKimDYKimDHLeeCBet alA comprehensive review on the pharmacokinetics and DrugDrug Interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist
US$ 26.38
US$ 24.61
US$ 23.89
US$ 20.24
US$ 23.16
US$ 27.84
US$ 29.16
US$ 26.79
US$ 21.01
US$ 28.44
US$ 25.72
